Millennium Initiates Phase II Trial To Evaluate MLN3897 In Rheumatoid Arthritis

Wed, 29 Nov 2006 02:00 PM EST

... Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the initiation of a randomized, double-blind, placebo-controlled Phase II study of MLN3897 in patients with rheumatoid arthritis (RA). MLN3897, an oral, small molecule designed to block CCR1, is a chemokine receptor believed to play a role in a number of inflammatory disorders including RA. [click link for full article] ...